EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world retention rate of secukinumab in patients with axial spondyloarthritis: Multi-centric retrospective data from China

Zhongchao Fu, Lin Wen, Ting Wu, Xinpeng Chen, Xiaoyu Liu, Sishi Huang, Lijun Zhang, Rangeng Shi, Xiaogui Cheng iD, Jinxian Huang iD

Rheumatology and Immunology Research · 13.07.2026 · 7 (2) · 85-94

DOI: 10.1515/rir-2026-0010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Rheumatology and Immunology Research, online erschienen am 13.07.2026. Verfasst von Zhongchao Fu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Department of Medicine, The Third Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong Province, China. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Objective Secukinumab (SEC), an interleukin 17A inhibitors (IL-17Ai) has been shown to be effective in managing axial spondyloarthritis (axSpA). However, data on its long-term retention in Chinese populations remain limited. This study aims to evaluate the retention rate of SEC in axSpA and its predisposing factors in Chinese patients.

Methods

We conducted a retrospective cohort study across three centers, including axSpA patients treated with SEC. Prescription records were retrieved from the hospital information system (HIS) and electronic medical records were reviewed to confirm diagnoses and treatment exposures. Retention rates at 12, 24, and 36 months were estimated using Kaplan-Meier analysis. Cox proportional hazards regression assessed the impact of prior biologic therapy and dosage on discontinuation risk. Discontinuation events were also evaluated.

Result

A total of 459 patients were identified and included, with the longest treatment follow-up period reaching 42 months. The overall drug retention rates for SEC were 76.1%, 68.7%, and 62.8% at 12, 24, and 36 months, respectively. Biologics-naïve patients exhibited a higher 12-month retention rate (80.7%) compared to biologic-experienced patients (72.5%). Among biologic-experienced patients, the 12-month retention rates progressively decreased with an increasing number of prior biologics: 74.6% for one prior biologic, 72.0% for two, and 55.3% for three. No statistically significant difference in retention rate was observed between the 300 mg and 150 mg groups ( P = 0.334). A total of 82 patients (17.86%) discontinued SEC. The primary reason for discontinuation was switching to alternative therapies ( n = 70, 85.4% of discontinuations).

Conclusion

SEC demonstrates robust retention rates in this Chinese axSpA cohort, particularly among biologics-naïve patients.

Schlagwörter

Stichwörter der Autor:innen

axial spondyloarthritisdiscontinuation patternretention ratesecukinumabswitching

Autor:innen und Institutionen

  • Division of Rheumatology, Department of Medicine, The Third Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong Province, China.
  • Division of Rheumatology, Department of Medicine, Ji'an Central People's Hospital, Ji'an, Jiangxi Province, China.
  • Division of Rheumatology, Department of Medicine, Shenzhen Futian Hospital for Rheumatic Diseases, Shenzhen, Guangdong Province, China.
  • Division of Rheumatology, Department of Medicine, The University of Hong Kong-Shenzhen Hospital, Shenzhen, Guangdong Province, China.
  • ShenZhen University Medical School, Shenzhen, Guangdong Province, China.
  • Department of Pharmacy, The Third Affiliated Hospital of Shenzhen University, Shenzhen, Guangdong Province, China.

ORCID-Profile: Xiaogui Cheng, Jinxian Huang

Zitieren

APA

Fu, Z., Wen, L., Wu, T., Chen, X., Liu, X., Huang, S., Zhang, L., Shi, R., Cheng, X., & Huang, J. (2026). Real-world retention rate of secukinumab in patients with axial spondyloarthritis: Multi-centric retrospective data from China. Rheumatology and Immunology Research, 7(2), 85-94. https://doi.org/10.1515/rir-2026-0010

Vancouver

Fu Z, Wen L, Wu T, Chen X, Liu X, Huang S, et al. Real-world retention rate of secukinumab in patients with axial spondyloarthritis: Multi-centric retrospective data from China. Rheumatology and Immunology Research. 2026;7(2):85-94. doi:10.1515/rir-2026-0010

BibTeX
@article{Fu2026,
  author = {Fu, Zhongchao and Wen, Lin and Wu, Ting and Chen, Xinpeng and Liu, Xiaoyu and Huang, Sishi and Zhang, Lijun and Shi, Rangeng and Cheng, Xiaogui and Huang, Jinxian},
  title = {Real-world retention rate of secukinumab in patients with axial spondyloarthritis: Multi-centric retrospective data from China},
  journal = {Rheumatology and Immunology Research},
  year = {2026},
  volume = {7},
  number = {2},
  pages = {85--94},
  doi = {10.1515/rir-2026-0010}
}
Kostenlos starten →